Accredited InvestorsEmployee ShareholdersInstitutionsPrivate Companies Who We Serve Trading and Investing Data Solutions Private Asset Custody Institutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Browse CompaniesIndividual InvestingForge MarketsFind new private company investment opportunities​Forge DataAnalyze private markets via Forge’s intuitive web application​Forge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Self-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRASolutions All Insights Private Market Reports Market Insights Buying and Selling Pre-IPO​ All Reports​Private Market UpdatesForge Investment OutlookStartup News and Trends​Private Market Data and Analytics​Tech IPO Calendar for 2024​Private Market Explained​Buying Pre-IPO Shares​Selling Pre-IPO SharesGlossaryVideosFAQsInsights About UsLeadershipInvestor RelationsPeople & CultureCareers About
Log InSign Up
Who We Serve
Solutions
Insights
About
Who We Serve
Solutions
Trading and Investing
Institutional Trading
Individual Investing
Data Solutions
Private Asset Custody
Self-Directed IRA
Insights
Private Market Reports
Market Insights
Buying and Selling Pre-IPO​
About
Log In
Sign Up
Secondary Marketplace / Trade Private Companies / Buy and Sell CytoVale Stock

CytoVale Stock

www.cytovale.com/Healthcare / Healthcare providers & servicesFounded: 2013

CytoVale is a biotechnology research company that uses early detection strategies for auto-immune diseases. The company has a mission of using diagnostic interventions to create faster, easier-to-implement medical treatment for patients. Other features of CytoVale are microfluidics and biophysical machine learning. CytoVale was founded by Ajay Shah and Dino Di Carlo in 2013 and is headquartered in San Francisco, CA.

Buy or sell CytoVale stockLearn more about CytoVale IPO

Register To Buy and Sell Shares

For more details on private stock price information, financing and valuation for CytoVale, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access CytoVale’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like CytoVale.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

CytoVale investors also invested in these private companies

Norwest Venture Partners
Western Technology Investment
National Science Foundation
Grids Capital
Baidu Ventures
Google for Startups Accelerator
National Institutes of Health
Sands Capital
Dolby Family Ventures
Breakout Ventures
U.S. Department of Health and Human Services
Global Health Investment Fund
Kayyak Ventures
Pathway Bioventures
Biomedical Advanced Research and Development Authority
Blackhorn Ventures
Pactolus Ventures
Farmore Capital Group
Breakout Labs
NetScientific

Team

Management Team

Ajay Shah Ph.D
Co-Founder & Chief Executive Officer
Bill Blackledge
Chief Financial Officer
Henry Tse Ph.D
Co-Founder & Chief Technology Officer
Robert Scoggins Ph.D
Chief Medical Officer
Dino Di Carlo Ph.D
Co-Founder & Scientific Advisor

Board Members

David Dolby
Dolby Family Ventures
Jack Fuchs
Blackhorn Ventures
Jordanna Schutz
Pactolus Ventures
Lindy Fishburne
Breakout Labs
Pascal Levensohn
Dolby Family Ventures

CytoVale stock FAQs

plusminus

Can you buy CytoVale stock?

As CytoVale is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private company like CytoVale, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not an accredited investor, discover how to begin the process to potentially qualify for new investment opportunities.
plusminus

How to buy CytoVale stock?

To invest in a private company like CytoVale through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)
  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell CytoVale stock?

Yes, you may be able to sell your CytoVale stock, subject to certain conditions. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company's interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell CytoVale stock?

If you hold private company shares of - whether as an employee or an early investor - Forge can help you sell them.
  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your CytoVale stock on our platform.
  3. Work with your dedicated Private Market Specialist who'll help guide you through every step of the transaction.
plusminus

Is CytoVale a public company?

No, CytoVale is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is CytoVale’s stock price?

CytoVale is a privately held company and therefore does not have a public stock price. However, you may access CytoVale’s private market stock price with Forge Data.
plusminus

What is CytoVale’s stock ticker symbol?

CytoVale does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Other companies like CytoVale in the Healthcare providers & services sector

Mark Cuban Cost Plus Drug Company
Sector
Healthcare / Healthcare providers & services
 
 
Carrot
Sector
Healthcare / Healthcare providers & services
Last Round Est. Valuation
$611.49MM
Thrive Global
Sector
Healthcare / Healthcare providers & services
Last Round Est. Valuation
$724.52MM
Devoted Health
Sector
Healthcare / Healthcare providers & services
Last Round Est. Valuation
$12.89B
Tend
Sector
Healthcare / Healthcare providers & services
Last Round Est. Valuation
$881.07MM
VillageMD
Sector
Healthcare / Healthcare providers & services
 
 
Monogram Health
Sector
Healthcare / Healthcare providers & services
 
 
Curative
Sector
Healthcare / Healthcare providers & services
Last Round Est. Valuation
$37.8MM
Papa
Sector
Healthcare / Healthcare providers & services
Last Round Est. Valuation
$1.39B
Fierce Biotech 11/16/2023

Cytovale collects $84M to roll out its rapid ER sepsis diagnostic test

After recently launching its emergency room-focused diagnostic for catching early cases of sepsis, Cytovale has raised $84 million in venture capital funding to bolster the system’s rollout. According to the San Francisco-based company, sepsis contributes to more than one-third of all in-hospital deaths—more than 350,000 annually in the U.S.—with about 80% of patients with the bloodstream condition spending at least some time in the ER.
Medical Device Network 01/19/2023

Cytovale’s test gets FDA 510(k) clearance for early sepsis detection

Medical diagnostics company Cytovale has secured 510(k) clearance from the US Food and Drug Administration (FDA) for IntelliSep, its test for the early detection of sepsis. IntelliSep has been designed to help clinicians recognise sepsis and make time-sensitive critical decisions. It provides test results within ten minutes. It is claimed to be the first FDA-approved diagnostic tool for evaluating cellular host response to help identify patients with sepsis in emergency departments.
Browse More Insights
Trending Companies

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.